

1 April 2026

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Block Listing Return

The Company makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:

Name of <i>applicant</i> :		Cambridge Cognition Holdings plc		
Name of scheme:		Share Options		
Period of return:	From:	1 October 2025	To:	31 March 2026
Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission:		1,000,000 ordinary shares of £0.01 each in the Company admitted to trading on 23 March 2023		
Balance of unallotted securities under scheme(s) from previous return:		466,316 ordinary shares		
<u>Plus</u> : The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil		
<u>Less</u> : Number of <i>securities</i> issued/allotted under scheme(s) during period:		Nil		
<u>Equals</u> : Balance under scheme(s) not yet issued/allotted at end of period:		466,316 ordinary shares		

Name of contact:	Simon McKeating
Telephone number of contact:	+44 (0)1223 810700

Enquiries:

Cambridge Cognition Holdings plc

Rob Baker, Chief Executive Officer

Ronald Openshaw, Chief Financial Officer

Adam Michael, Head of Corporate Communications

Tel: +44 1223 810700

press@camcog.com

Panmure Liberum Limited (NOMAD & Joint Broker)

Will Goode / Mark Rogers / Freddy Crossley

Rupert Dearden

(Corporate Finance)

(Corporate Broking)

Singer Capital Markets Limited (Joint Broker)

Amber Higgs / James Serjeant / Daniel Ingram

Tel: +44 20 7496 3000

ABOUT CAMBRIDGE COGNITION AND CANTAB PATHWAY™

Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments support scientific discovery, accelerate drug development and improve patient care.

The Company has developed a suite of touchscreen and voice-based cognitive assessments delivered under the **CANTAB** and **Winterlight** brands. These assessments are designed to:

- require minimal specialist administration
- deliver objective results in real time or shortly after completion
- reduce administrator bias
- support longitudinal monitoring of cognitive function

Assessment results can be presented in formats appropriate for both consumers in home-use settings and healthcare professionals in clinical or research environments.

CANTAB Pathway™ is Cambridge Cognition's latest scalable cognitive assessment solution, structured as an escalating series of tasks for use in consumer and healthcare settings:

- **CANTAB One™** - a brief assessment of overall cognitive function
- **CANTAB Insight™** - a three-task battery providing deeper insight across five cognitive sub-domains
- **CANTAB Plus™** - specialist disease-specific modules for use by appropriately qualified healthcare professionals, covering eight indications including Parkinson's disease, ADHD, multiple sclerosis, Huntington's disease, schizophrenia, depression, and Alzheimer's disease and related dementias

For further information, visit: www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCEALDFDAPKEFA